Holen Sie sich die Stockscreener-App
1.59
3.05%
-0.05
Vorhandelsmarkt:
1.83
0.24
+15.09%
Schlusskurs vom Vortag:
$1.64
Offen:
$1.64
24-Stunden-Volumen:
2.73M
Relative Volume:
2.30
Marktkapitalisierung:
$192.18M
Einnahmen:
$257.24M
Nettoeinkommen (Verlust:
$-237.89M
KGV:
-0.6115
EPS:
-2.6
Netto-Cashflow:
$-175.17M
1W Leistung:
-4.22%
1M Leistung:
+13.57%
6M Leistung:
+72.40%
1J Leistung:
+21.37%
1-Tages-Spanne:
$1.57
$1.67
1-Wochen-Bereich:
$1.5103
$1.67
52-Wochen-Spanne:
$0.71
$1.89
Coherus Oncology Inc Stock (CHRS) Company Profile
Firmenname
Coherus Oncology Inc
Sektor
Branche
Telefon
(650) 649-3530
Adresse
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Vergleichen Sie CHRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.59 | 198.23M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.35 | 117.00B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 78.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
827.02 | 50.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
370.00 | 48.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.81 | 37.81B | 4.98B | 69.59M | 525.67M | 0.5197 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Hochstufung | Maxim Group | Hold → Buy |
| 2024-08-16 | Herabstufung | UBS | Buy → Neutral |
| 2023-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2023-07-24 | Eingeleitet | Citigroup | Buy |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2023-03-28 | Hochstufung | UBS | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Neutral |
| 2022-03-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-16 | Eingeleitet | BofA Securities | Neutral |
| 2020-04-17 | Eingeleitet | SunTrust | Buy |
| 2019-08-13 | Eingeleitet | Mizuho | Buy |
| 2019-08-02 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-02 | Bestätigt | Maxim Group | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-09 | Bestätigt | Maxim Group | Buy |
| 2017-08-08 | Bestätigt | JP Morgan | Overweight |
| 2017-06-13 | Bestätigt | Maxim Group | Buy |
| 2017-05-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2016-10-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-09-07 | Eingeleitet | Maxim Group | Buy |
| 2016-07-27 | Eingeleitet | Citigroup | Buy |
| 2016-01-20 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Coherus Oncology Inc Aktie (CHRS) Neueste Nachrichten
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Oppenheimer initiates Coherus Biosciences stock with Outperform rating By Investing.com - Investing.com Canada
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above 200-Day Moving AverageHere's Why - MarketBeat
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference - 富途资讯
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape - The AI Journal
CHRS: Pivotal 2026 data readouts expected for innovative oncology assets, with sales growth on track - TradingView — Track All Markets
January 2026 Penny Stock Spotlight: Three Promising Picks - simplywall.st
Can Coherus Oncology Inc. (8C5) stock survive global slowdownDividend Hike & Growth Focused Entry Reports - Улправда
There's No Escaping Coherus Oncology, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 27% Share Price Rise - simplywall.st
How Coherus Oncology Inc. (8C5) stock valuation compares with sectorOil Prices & Stepwise Swing Trade Plans - Улправда
Coherus Oncology (NASDAQ:CHRS) Stock Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Coherus Biosciences Divests UDENYCA Business - MSN
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 - FinancialContent
Coherus publishes data on tagmokitug antibody for cancer treatment By Investing.com - Investing.com Nigeria
Coherus (CHRS) Reports Promising Results for Anti-CCR8 Antibody in Cancer Treatment - GuruFocus
Coherus Oncology Introduces Tagmokitug: Promising Results from CCR8-targeting Antibody Research - Quiver Quantitative
Coherus publishes data on tagmokitug antibody for cancer treatment - Investing.com
Coherus Oncology Announces Publication in Molecular Cancer - GlobeNewswire
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) - Chartmill
What analysts say about Coherus Oncology Inc 8C5 stockMarket Insider Reports & Outstanding Growth Opportunities - earlytimes.in
Will Coherus Oncology Inc 8C5 stock outperform Dow Jones2025 Market Trends & Accurate Intraday Trading Signals - moha.gov.vn
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Coherus Oncology (NASDAQ:CHRS) Stock Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Coherus Oncology: A Two-Pronged March With Mid-2026 Implications (CHRS) - Seeking Alpha
Coherus Oncology, Inc.(NasdaqGM: CHRS) added to NASDAQ Biotechnology Index - marketscreener.com
Coherus Oncology (CHRS) price target increased by 13.33% to 5.78 - MSN
Coherus Oncology (CHRS) Price Target Increased by 13.33% to 5.78 - Nasdaq
Aug Shorts: How Coherus Oncology Inc. (8C5) stock valuation compares with sectorQuarterly Portfolio Review & AI Driven Stock Price Forecasts - Улправда
CEO Moves: How Coherus Oncology Inc. (8C5) stock valuation compares with sectorMarket Weekly Review & Risk Controlled Stock Pick Alerts - Улправда
Support Test: Can Coherus Oncology Inc. (8C5) stock survive global slowdownJuly 2025 Macro Moves & Smart Swing Trading Techniques - Улправда
Will Coherus Oncology Inc. (8C5) stock deliver stable dividends2025 Dividend Review & Breakout Confirmation Alerts - Улправда
CHRS: 2026 will be pivotal with major data readouts for novel immuno-oncology therapies - TradingView — Track All Markets
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200 Day Moving AverageTime to Sell? - MarketBeat
Coherus Oncology Earnings Notes - Trefis
LOQTORZI plus chemotherapy shows 31-month survival benefit in cancer study - Investing.com Australia
Coherus BioSciences stock jumps after positive cancer drug survival data By Investing.com - Investing.com UK
Coherus BioSciences stock jumps after positive cancer drug survival data - Investing.com
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma - The Manila Times
Coherus Oncology (CHRS) price target decreased by 11.77% to 5.10 - MSN
Why Coherus Oncology Inc. (8C5) stock stays on top picksTrade Risk Summary & Daily Technical Forecast Reports - Newser
Why global investors buy Coherus Oncology Inc. (8C5) stockJuly 2025 Earnings & Expert Verified Movement Alerts - Newser
Does Coherus Oncology Inc. (8C5) stock trade below intrinsic valueMarket Volume Summary & Community Consensus Stock Picks - Newser
Why Coherus Oncology Inc. (8C5) stock could rally strongly2025 Trading Volume Trends & Free Safe Entry Trade Signal Reports - Newser
Can Coherus Oncology Inc. (8C5) stock sustain free cash flow2025 Macro Impact & AI Enhanced Trading Alerts - Newser
Coherus Oncology, Inc. (NASDAQ:CHRS) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough - 富途牛牛
Can Coherus Oncology Inc. (8C5) stock hold up in economic slowdownTrade Risk Assessment & Fast Gain Stock Tips - Newser
How strong is Coherus Oncology Inc. (8C5) stock earnings growthAnalyst Downgrade & Safe Entry Zone Identification - Newser
Coherus Oncology (CHRS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Finanzdaten der Coherus Oncology Inc-Aktie (CHRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.46%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):